SCHEMBL6525259

SCHEMBL6525259

CN(C)S(=O)(=O)Nc1ccc2c(c1)CC(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.56
HPGD P15428 4/20 0.53
MAPT P10636 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HSD17B10 Q99714 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
IDO1 P14902 1/20 0.47
AHR P35869 1/20 0.46
KIF11 P52732 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMYD3 Q9H7B4 1/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 2/20 0.43
BCL6 P41182 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL153164 0.84 PKM (0.60) PKMMAPTTDP1IDO1AHR
SCHEMBL29554536 0.77 PKM (0.53) PKMMAPTTDP1IDO1AHR
SCHEMBL5636293 0.77 PKM (0.73) PKMMAPTSMN1; SMN2TDP1GAA
SCHEMBL12361998 0.77 AHR (0.56) PKMMAPTTDP1IDO1AHR
SCHEMBL5167999 0.76 PKM (0.65) PKMMAPTTDP1IDO1GAA
SCHEMBL689464 0.75 GAA (0.56) PKMMAPTTDP1IDO1AHR
SCHEMBL3038643 0.74 TDP1 (0.65) PKMMAPTTDP1IDO1AHR
SCHEMBL31681272 0.73 PKM (0.65) PKMMAPTTDP1IDO1GAA
SCHEMBL23066125 0.73 AHR (0.51) PKMMAPTTDP1IDO1AHR
SCHEMBL13996622 0.73 AHR (0.51) PKMMAPTTDP1IDO1AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 PKM 958/4885HPGD 2447/4885MAPT 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.